Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2a, randomized, double-blind, placebo-controlled,dose-escalation study to evaluate the safety and tolerability of multiple-dose subcutaneous administration of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody,when administered to adults with mild persistent asthma

Next Previous
Trial Profile

A phase 2a, randomized, double-blind, placebo-controlled,dose-escalation study to evaluate the safety and tolerability of multiple-dose subcutaneous administration of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody,when administered to adults with mild persistent asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enokizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors MedImmune

Most Recent Events

  • 29 Oct 2008 Results were presented at CHEST 2008.
  • 05 Oct 2008 Status changed from suspended to completed, based on information from ClinicalTrials.gov.
  • 25 Aug 2008 Status changed from active, no longer recruiting to suspended, based on information from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top